EORTC Head and Neck Cancer Group

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
24001
Randomized phase III study on the selection of the target volume in postoperative radiotherapy for cervical lymph node metastases of squamous cell carcinoma from an unknown primary (CUP)
24981
A feasibility study of primary chemotherapy followed by concomitant chemoradiation with or without amifostine in patients with locally advanced undifferenciated nasopharyngeal cancer (UNPC).
24982
Phase II study on Gemcitabine in Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck
22996
A phase III double-blind, randomized, placebo-controlled study of Erythropoietin when used as an adjuvant to radiation therapy in patients with head and neck squamous cell carcinoma. EORTC 22996-24002
24971
A randomized phase III multicenter trial of neoadjuvant docetaxel (Taxotere) plus cisplatin plus 5-fluorouracil versus neoadjuvant cisplatin plus 5-fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck
24954
Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy versus alternating chemo-radiotherapy in resectable hypopharynx and larynx cancers (Jointly with the EORTC Radiotherapy Cooperative Group)
24922
Randomized phase II trial of Methotrexate vs two schedules of Taxol in patients with advanced squamous cell carcinoma of the head and neck
24921
Phase II study of Interferon alpha and 5-fluorouracil in locally advanced or recurrent or metastatic squamous cell carcinoma of the head and neck
24891
Is laryngeal preservation with induction chemotherapy safe in the treatment of hypopharyngeal squamous cell carcinoma ? A randomized phase III trial
24882
Phase II study of mitoxantrone in recurrent or metastatic adenoid cystic carcinoma of the head and neck
24881
Phase II study of Epirubicin and Cisplatin in advanced nasopharyngeal carcinoma (NFC)
24873
PHASE II STUDY OF PIRARUBICIN (THP) IN PATIENTS WITH ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.
24872
Randomized phase III trial of methotrexate vs 10-EdAm, a new methotrexate analogue,in patients with advanced squamous cell carcinoma of the head and neck
24871
EUROSCAN: Phase III randomized trial of chemoprevention with vitamin A and N-acetylcysteine in patients curatively treated for carcinomas of the larynx, oral cavity and lung. (Jointly with the EORTC Lung Cancer Cooperative Group : Protocol 08871)
24861
Phase III Randomized Comparison of Chemotherapy with CDDP/5-FU Followed by Radiotherapy vs Radical Surgery with or without Radiotherapy in Patients with Nonmetastatic Squamous Cell Carcinoma of the Larynx
24863
Phase II Randomized Chemotherapy Trial of CHIP vs CACP in Patients with Advanced Ovarian Cancer Refractory or Recurrent After First-Line Chemotherapy with CBDCA (Summary Last Modified 05/88
24851
PHASE II STUDY OF 4'-EPIDoxorubicin IN RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK.
24844
5-FU/CDDP FOLLOWED BY SURGERY AND RADIOTHERAPY vs SURGERY AND RADIOTHERAPY IN ADVANCED SQUAMOUS CELL CARCINOMA OF LATERAL OROPHARYNX AND LATERAL POSTERIOR ORAL CAVITY (Phase III trial)
24842
Randomized trial of cisplatin, methotrexate, bleomycin and vincristine (CABO) vs cisplatin and 5-fluorouracil (CF) vs cisplatine alone (C) in patients with advanced squamous cell carcinoma of the head and neck.
24941
A randomized phase III study of supportive care plus Methotrexate versus supportive care only in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
22071
Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence
24061
Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies
24051
Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell.

Back to Group-list